IBRX 8-K 2026-11-09
ImmunityBio, Inc. (IBRX) 8-K dated 2026-11-09 — accession 0001326110-26-000097.
ImmunityBio, Inc. (IBRX) is a biotechnology company listed on US.
IBRX sales +53% YoY
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
Not investment advice. The IBRX SEC hub lists recent forms. The stock page is the research view.
- YoY
- +53%
- Guidance
- expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “is,” “seeks,” “should,” “will,” “strateg
Why it matters
- expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “is,” “seeks,” “should,” “will,” “strateg
- We continue to see more physicians prescribing ANKTIVA to multiple patients and growing physician interest in our chemotherapy-free approach in the U.S.